A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer

• Autor(a) principal: Moreira, João N.
• Data de Publicação: 2001
• Outros Autores: Hansen, Christian B., Gaspar, Rogério, Allen, Theresa M.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/5798; https://doi.org/10.1016/S0005-2736(01)00386-8
• topic: Antagonist G; Targeting; Pegylated liposome; Doxorubicin; Cytotoxicity; Small cell lung cancer

The ability of a growth factor antagonist, [-Arg6,-Trp7,9-NmePhe8]-substance P(6-11), named antagonist G, to selectively target polyethylene glycol-grafted liposomes (known as sterically stabilized liposomes) to a human classical small cell lung cancer (SCLC) cell line, H69, was examined. Our results showed that radiolabeled antagonist G-targeted sterically stabilized liposomes (SLG) bound to H69 cells with higher avidity than free antagonist G and were internalized (reaching a maximum of 13[punctuation space]000 SLG/cell), mainly through a receptor-mediated process, likely involving clathrin-coated pits. This interaction was confirmed by confocal microscopy to be peptide- and cell-specific. Moreover, it was shown that SLG significantly improved the nuclear delivery of encapsulated doxorubicin to the target cells, increasing the cytotoxic activity of the drug over non-targeted liposomes. In mice, [125I]tyraminylinulin-containing SLG were long circulating, with a half-life of 13 h. Use of peptides like antagonist G to promote binding and internalization of sterically stabilized liposomes, with their accompanying drug loads, i.e., anticancer drugs, genes or antisense oligonucleotides, into target cells has the potential to improve therapy of SCLC.